|
BIIB's Income from Cont. Operations Growth by Quarter and Year
Biogen Inc 's Income from Cont. Operations results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Income from Cont. Operations Growth Y/Y▼
|
Income from Cont. Operations Growth Y/Y▼
|
| BIIB Income from Cont. Operations (in millions $) |
FY 2022 |
FY 2021 |
FY 2020 |
FY 2019 |
| IV Quarter |
December |
-
|
-20.60
|
357.50
|
1,439.70
|
| III Quarter |
September |
-
|
318.10
|
703.90
|
1,545.90
|
| II Quarter |
June |
-
|
1,025.50
|
1,606.50
|
1,494.10
|
| I Quarter |
March |
218.50
|
404.60
|
1,392.60
|
1,408.80
|
| FY |
|
218.50
|
1,727.60
|
4,060.50
|
5,888.50
|
| BIIB Income from Cont. Operations first quarter 2022 Y/Y Growth Comment |
Biogen Inc reported drop in Income from Cont. Operations in the first quarter 2022 by -46% to $ 218.50 millions, from the same quarter in 2021.
The fall in the first quarter 2022 Biogen Inc 's Income from Cont. Operations compares unfavorably to the Company's average Income from Cont. Operations increase of 10.89%.
Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Income from Cont. Operations growth. While Biogen Inc ' s Income from Cont. Operations meltdown of -46% ranks overall at the positon no. 756 in the first quarter 2022.
|
| BIIB Income from Cont. Operations ( Y/Y Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
- |
-75.17 % |
52.37 % |
| III Quarter |
September |
- |
-54.81 % |
-54.47 % |
7.14 % |
| II Quarter |
June |
- |
-36.17 % |
7.52 % |
63.29 % |
| I Quarter |
March |
-46 % |
-70.95 % |
-1.15 % |
20.29 % |
| FY |
|
- |
-57.45 % |
-31.04 % |
31.62 % |
BIIB Income from Cont. Operations (Quarter on Quarter Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
- |
-49.21 % |
-6.87 % |
| III Quarter |
September |
- |
-68.98 % |
-56.18 % |
3.47 % |
| II Quarter |
June |
- |
153.46 % |
15.36 % |
6.05 % |
| I Quarter |
March |
- |
13.17 % |
-3.27 % |
49.1 % |
| FY (Year on Year) |
|
- |
-57.45 % |
-31.04 % |
31.62 % |
| Income from Cont. Operations Y/Y Growth Statistics |
| High |
Average |
Low |
| 413.15 % |
10.89 % |
-86.75 % |
| (Sep. 30, 2006) |
|
(June 30. 2006) |
|
|
| Income from Cont. Operations Y/Y Growth Statistics |
| High |
Average |
Low |
| 413.15 % |
10.89 % |
-86.75 % |
| (Sep. 30, 2006) |
|
(June 30. 2006) |
|
| Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022 |
Biogen Inc 's Q/Q Income from Cont. Operations Growth
| Income from Cont. Operations Q/Q Growth Statistics |
| High |
Average |
Low |
| 4345.95 % |
76.43 % |
-68.98 % |
| (Sep. 30, 2004) |
|
|
| BIIB's I. Quarter Q/Q Income from Cont. Operations Comment |
I. Quarter 2022Periodic Biogen Inc in the circumstances loss from continued operations of $ 218.50 millionsPeriodic circumstances appear to have contributed Biogen Inc 's restoration of profitability, as BIIB clinchesIncome from Cont. Operations of $ 218.50 millions in the I. Quarter 2022 emanate loss from continued operations-20.60 millions in the forth quarter. Biogen Inc announced in the I. Quarter 2022 Income from Cont. Operations of $ 218.50 millions compare to loss from continued operations recorded in previos quarter.
Within Biotechnology & Pharmaceuticals industry Biogen Inc achieved highest sequential Income from Cont. Operations growth. While Biogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 0. |
|
|
|
| Income from Cont. Operations Q/Q Growth Statistics |
| High |
Average |
Low |
| 4345.95 % |
76.43 % |
-68.98 % |
| (Sep. 30, 2004) |
|
|
| BIIB's I. Quarter Q/Q Income from Cont. Operations Comment |
I. Quarter 2022Cyclical Biogen Inc in the circumstances loss from continued operations of $ 218.50 millionsCyclical circumstances seem to have contributed Biogen Inc 's restoration of profitability, as BIIB postIncome from Cont. Operations of $ 218.50 millions in the I. Quarter 2022 emanate loss from continued operations-20.60 millions in the forth quarter. Biogen Inc announced in the I. Quarter 2022 Income from Cont. Operations of $ 218.50 millions compare to loss from continued operations recorded in previos quarter.
Within Biotechnology & Pharmaceuticals industry Biogen Inc achieved highest sequential Income from Cont. Operations growth. While Biogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 0. |
|
Biogen Inc 's 12 Months Income from Cont. Operations Growth Year on Year
Income from Cont. Operations TTM Growth |
12 Months Ending
(Mar 31 2022) |
12 Months Ending
(Dec 31 2021) |
12 Months Ending
(Sep 30 2021) |
12 Months Ending
(Jun 30 2021) |
12 Months Ending
(Mar 31 2021) |
| Cumulative Income from Cont. Operations 12 Months Ending |
$ 1,541.50 |
$ 1,727.60 |
$ 2,105.70 |
$ 2,491.50 |
$ 3,072.50 |
| Y / Y Income from Cont. Operations Growth (TTM) |
-49.83 % |
-57.45 % |
-59.05 % |
-58.37 % |
-47.68 % |
| Year on Year Income from Cont. Operations Growth Overall
Ranking |
# 737 |
# 268 |
# 60 |
# 1829 |
# 1524 |
| Seqeuential Income from Cont. Operations Change (TTM) |
-10.77 % |
-17.96 % |
-15.48 % |
-18.91 % |
-24.33 % |
| Seq. Income from Cont. Operations Growth (TTM) Overall
Ranking |
# 756 |
# 2046 |
# 70 |
# 396 |
# 138 |
| Cumulative Income from Cont. Operations growth
Comment |
Biogen Inc showed decline, but improvement compare to trailing twelve month Income from Cont. Operations decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Income from Cont. Operations fall would be -49.83% year on year to $1,542 millions.
In the Healthcare sector 53 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 268 to 737. |
| Income from Cont. Operations TTM Q/Q Growth Statistics |
| High |
Average |
Low |
413.15 % |
10.89 % |
-86.75 % |
|
|
|
|
|
| Income from Cont. Operations TTM Y/Y Growth Statistics |
| High |
Average |
Low |
1760.54 % |
57.8 % |
-78.16 % |
|
|
|
| Income from Cont. Operations TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 6 |
| Sector |
# 56 |
| S&P 500 |
# 756 |
|
| Cumulative Income from Cont. Operations growth
Comment |
Biogen Inc showed decline, but improvement compare to trailing twelve month Income from Cont. Operations decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Income from Cont. Operations drop would be -49.83% year on year to $1,542 millions.
In the Healthcare sector 53 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 268 to 737. |
| Income from Cont. Operations TTM Q/Q Growth Statistics |
| High |
Average |
Low |
413.15 % |
10.89 % |
-86.75 % |
|
|
|
| Income from Cont. Operations TTM Y/Y Growth Statistics |
| High |
Average |
Low |
1760.54 % |
57.8 % |
-78.16 % |
|
|
|
| Income from Cont. Operations TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 6 |
| Sector |
# 56 |
| S&P 500 |
# 756 |
|
